Effective March 15, 2026, Cigna’s IP0660 policy clarifies infliximab dosing and approval pathways for Crohn’s disease, ulcerative colitis, and indeterminate colitis by separating initial-therapy vs. continuation (currently receiving) criteria. Initial therapy generally follows induction at weeks 0, 2, and 6 with maintenance most commonly no more frequently than every 8 weeks and initial approvals for 6 months; continuation approvals require objective or symptomatic benefit and are issued for 1 year. For patients already on infliximab, maximum dosing is specified as up to 10 mg/kg IV no more frequently than every 4 weeks across indications, with some indication-specific maintenance options (every 6 or 4 weeks) noted. Guideline references (ACG, AGA, NCCN, EULAR, AAD/NPF, etc.) are cited to support indication-specific placement and non-gastroenterology dosing exceptions (e.g., immunotherapy-related toxicities, HS, Behçet’s).
March 2026 Revision: Infliximab Dosing and Continuation Criteria
Summary of revisions in this version
This revision (effective 2026-03-15) clarifies and consolidates the coverage and dosing criteria for infliximab products across multiple gastroenterology-related indications within Cigna's IP0660 drug coverage framework. Key structural clarifications include distinct initial-therapy versus continuation (currently receiving) pathways for dosing and approval duration across Crohn's disease, Ulcerative colitis, and Indeterminate colitis. The document also uniformly specifies maximum dose limits for patients currently receiving infliximab products (up to 10 mg/kg IV no more frequently than every 4 weeks) across multiple indications.
The revision explicitly aligns dosing frequencies for initial therapy regimens (induction at weeks 0, 2, and 6) and then indicates maintenance intervals (most commonly no more frequently than every 8 weeks, with some indication-specific options for every 6 or 4 weeks where noted). It also incorporates guideline references (ACG, AGA, NCCN, EULAR, AAD/NPF) into the rationale sections, reinforcing where infliximab is considered an appropriate advanced therapy option or recommended by specialty societies.
Coverage Duration and Clinical Criteria by Indication (`Crohn's`, `Ulcerative colitis`, `Indeterminate colitis`)
Indication-specific approval pathways and durations
For Crohn's disease, the policy provides two pathways: an initial therapy pathway that approves infliximab for 6 months for patients ≥ 6 years of age when prescribed by or in consultation with a gastroenterologist; and a continuation pathway that approves 1 year of therapy for patients established on therapy for ≥ 6 months. Continuation approval requires either objective evidence of benefit (e.g., fecal calprotectin, CRP, MRE/CTE, endoscopy, or steroid-sparing) or symptomatic improvement compared to baseline.
For Ulcerative colitis, there is a parallel structure: initial therapy approvals for 6 months (patients ≥ 6 years and gastroenterology involvement), and 1-year continuation approvals for patients established on therapy ≥ 6 months who demonstrate objective or symptomatic benefit. Indeterminate colitis has a stricter initial-therapy path: initial approval for 6 months requires age ≥ 6 years, prior trials of one systemic corticosteroid, mesalamine, and either azathioprine or 6-mercaptopurine, plus gastroenterology involvement. Continuation criteria mirror other colitides with a 1-year approval when benefit is documented.
Dosing Schedules and Maximum `10 mg/kg` Continuation Limit
Dosing regimens and maximum dose limits across indications
The policy consistently defines an induction regimen of infliximab as doses at week 0, 2, and 6, with the commonly approved maintenance interval of no more frequently than every 8 weeks for initial therapy maintenance. Some indication statements include maintenance frequency of every 6 weeks (noted in an earlier dosing statement) or allow higher-frequency dosing only under the "patient currently receiving an infliximab product" pathway. For patients already on an infliximab product, the documented allowable maximum is 10 mg/kg IV no more frequently than every 4 weeks.
Specific indication dosing entries vary slightly by approved mg/kg for initial therapy (e.g., up to 5 mg/kg for many indications, and 3 mg/kg for certain other indications noted), but the unifying administrative rule is separation of initial versus continuation regimens and explicit maximums for those already established on therapy. The policy also provides alternate induction dosing for select non-gastroenterology indications and immunotherapy-related toxicity dosing (up to 10 mg/kg induction in that context).
Guideline Context and Other Indications (e.g., immunotherapy toxicities, HS, Behcet's)
Role of clinical guidelines and non-gastroenterology uses referenced in the policy
The policy cites multiple specialty guidelines to frame clinical appropriateness: the ACG and AGA guidance (2024–2025) endorses advanced therapies including TNF inhibitors for moderate to severe Crohn's disease and Ulcerative colitis and notes corticosteroid-sparing strategies. Dermatology guidance (AAD/NPF) and European Dermatology Forum recommendations are referenced for plaque psoriasis positioning. Rheumatology (ACR) and ophthalmology (AAO) or EULAR guidelines are cited where infliximab has recommended roles for psoriatic arthritis, rheumatoid arthritis, Behcet's disease, and sight-threatening uveitis.
The policy also specifies non-gastroenterology use cases where infliximab dosing and approval durations differ, for example: immunotherapy-related toxicities associated with checkpoint inhibitors (NCCN reference), where induction dosing may be approved up to 10 mg/kg and maintenance intervals differ. Hidradenitis suppurativa is explicitly noted as a condition where infliximab is a recommended therapy per HS foundation guidance. These guideline citations are embedded to support indication- and scenario-specific coverage statements within IP0660.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.